Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > New Press Release - Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 19, 2024 5:31pm

82 Views

Post# 36231973

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Learn to read Buckeroo .... I repeated what Kirk Look said last week, which was the Bracelet-1 OS results were imminent. And those results were released today, which was as close to imminent as one would expect. And if a deal is imminent, then I would like to hear that from Kirk Look as well.

<< Previous

Bullboard Posts

Next >>

Osisko Development receives permits for Cariboo Gold Project